tag:blogger.com,1999:blog-3741684961227307530.post7118152550739674282..comments2024-01-05T05:58:19.437-08:00Comments on Medical Quack: Doctor Wes Speaks on on Doctor Privacy And Ongoing Fire Sales Of Medical DataMedical Quackhttp://www.blogger.com/profile/12443589277651479846noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-3741684961227307530.post-43768432479578339902011-04-29T00:02:49.766-07:002011-04-29T00:02:49.766-07:00I wish the same were true for consumers as ours is...I wish the same were true for consumers as ours is not protected with prescription data and it is being used all over the place and sold.Medical Quackhttps://www.blogger.com/profile/12443589277651479846noreply@blogger.comtag:blogger.com,1999:blog-3741684961227307530.post-87356715067876876272011-04-28T13:26:48.099-07:002011-04-28T13:26:48.099-07:00The AMA’s role in sharing physician demographic da...The AMA’s role in sharing physician demographic data has real benefits for physicians. With the help of the AMA, physicians can exert control over pharmaceutical companies who want access to physician prescribing data. <br /><br />Physicians can use the AMA’s Physician Data Restriction Program (PDRP) to designate their prescription data as off-limits to drug salespeople and register complaints against pharmaceutical companies that use the data inappropriately. The program is free and any physician can enroll in the service regardless of AMA membership.<br /> <br />The PDRP provides a balanced approach for addressing the diverse concerns surrounding the use of physician prescribing data. It gives the AMA the ability to intercede on behalf of physicians against unwanted use of prescribing data by pharmaceutical sales representatives, while preserving prescription data for public good purposes, such as medical research, quality improvement, drug diversion detection and drug recall notices.<br /> <br />The release of prescription data to pharmaceutical companies does not seem to be a significant issue for most physicians. A Gallup survey that found 84 percent of physicians either were not concerned about the release of individual prescribing data or felt that the ability to “opt-out” of the release of their data to pharmaceutical sales representatives would alleviate their concerns. The AMA’s PDRP accomplishes this "opt out" capability. A subsequent market research study indicated that 96 percent of physicians participating in the PDRP were either satisfied or very satisfied with the program.<br /> <br />Restricting access to prescribing data should be every physician's individual choice. Only the AMA can guarantee the nation’s physicians have that choice and control, while ensuring the data remains available for public good purposes. Without the AMA to protect physician interests, it’s likely that private companies would step-in and ignore the choice physicians deserve.<br /> <br />Cecil B. Wilson, M.D.<br />President, American Medical AssociationCecil B Wilson MDhttp://www.ama-assn.org/go/pdrpnoreply@blogger.com